EE552 Importance of Half Cycle Correction for Cost-Effectiveness Analysis: Case Study of Sacubitril/Valsartan Vs in Enalapril Heart Failure with Reduced Ejection Fraction

For products indicated for chronic heart failure with reduced ejective fraction (HFrEF) half-cycle correction might be of increased importance to capture effect of survival gains and reduction in hospitalizations. To understand the importance and effect of half-cycle correction in cost-effectiveness analysis for Sacubitril/Valsartan vs Enalapril in HFrEF.